Improvement of spontaneous speech in early stage Alzheimer's disease with rivastigmine

Journal of Nutrition, Health and Aging

Volumn 13, Issue 1, 2009, Pages 34-38

  Visch Brink, Evy G ^a   Van Rhee Temme, W ^b   Rietveld, T ^b   Krulder, J W M ^a   van Harskamp, F ^a   Van Der Cammen, T J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LANGUAGE ABILITY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPEECH ANALYSIS; SPEECH DISCRIMINATION; SPEECH DISORDER;

EID: 60349101479     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0007-z     Document Type: Article

References (51)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease (review). Cochrane Library 2007, issue 3.
2. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer's disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004;3:123-128.
3. Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41.
4. Almkvist O, Darreh-Shon T, Stefanova E, Spiegel R, Nordberg A. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J neurol 2004,11, 253-261.
5. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res 2006;34:339-47.
6. Onor ML, Trevisiol M, Aguglia E. Rivastiginine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2007;2:17-32.
7. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388-397.
8. Doraiswarny PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, Veach J. Long-term effect of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002;26:705-712.
9. Frankfort SV, Appels BA, de Boer A, Tulner LR, van Campen JPCM, Koks CHW, Beijnen JH, Schmand BA. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiol Drug Saf 2007;16:545-551.
10. Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord 2005;20:192-197.
11. Schneider LS. Treatment of Alzheimer's Disease. In: Katz I, ed. Annual review of gerontology and geriatrics: Focus on psychopharmacologic interventions in late life. 19. New York: Springer Publishing, 2000:120-135.
12. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
13. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stäbelin HB, Hartman R, Ghabarawi M, on behalf of the B303 Exelon Study Group: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Br Med J 1999;318:633-640.
14. Feldman HH, Lane R, on behalf of the Study 304 Group. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007;78:1056-1063.
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
16. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003;60:843-848.
17. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59: 817-822.
18. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, van den Bussche H. Cholinestrase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br Med J 2005;331: 321-327.
19. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care 2002;18:497-507.
20. Nicholas M, Obler LK, Au R, Albert ML, Helm-Estabrooks N. Empty speech in Alzheimer's disease and fluent aphasia. J Clin Exp Psychol 1985;8:75-92.
21. Iles J. Neurolinguistic features of spontaneous language production dissociate three forms of neurodegenerative disease: Alzheimer's, Huntington's and Parkinson's. Brain Lang 1989;37:628-642.
22. Singh S, Bucks RS, Coerden JM. Evaluation of an objective technique for analysing temporal variables in DAT spontaneous speech. Aphasiology 2001;15 (6):571-583.
23. Bschor T, Kuhl KP, Reischies FM. Spontaneous speech of patients with dementia of the Alzheimer type and mild cognitive impairment. hit Psychogeriatr 2001;13:289-298.
24. Forbes K, Venneri A, Shanks F. Distinct patterns of spontaneous speech deterioration: an early predictor of Alzheimer's disease. Brain and Cognition 2002;48:356-361.
25. Henry JD, Crawford JR, Phillips LH. Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia 2004;42:1212-1222.
26. Forbes-McKay KE, Venneri A. Detecting subtle spontaneous language decline in early Alzheimer's disease with a picture description task. Neurol Sci 2005;26:243-54.
27. Guendouzi J, Müller N. Approaches to discourse in dementia. Mahwah-London: Lawrence Erlbaum Associates 2006.
28. Prins R, Prins ND, Visch-Brink EG. Taalstoomissen bij dementie. In: Stem-Spraak-Taalpathologie 2002;B13.3.
29. Bucks RS, Singh S, Cuerden JM, Wilcock GK. Analysis of spontaneous conversational speech in dementia of the Alzheimer type: Evaluation of an objective technique for analysing lexical performance. Aphasiology 2000;14:71-91.
30. Orange JB, Kertesz A. Discourse analysis and dementia. Brain Lang 2000;71:172-174.
31. Blanken G, Dittman JC, Haas JC, Wallesch C-W. Spontaneous speech in senile dementia. Cognition 1987;27:247-274.
32. Ulatowska HK, Allard L, Bond Chapman S. Narrative and procedural discourse in aphasia. In: Joanette Y, Brownell HH, eds. Discourse ability and brain damage: Theoretical and empirical perspectives. New York: Springer Verlag, 1990, 180-194.
33. De Santi S, Koenig L, Obler KL, Goldberger J. Cohesive devices and conversational discourse in Alzheimer's Disease. In: Bloom LR, Obler LY, de Santi S, Ehrlich JS. Discourse analysis and applications. Hillsdale/ Hove: Lawrence Erlbaum Associates, 1994.
34. Romero B, Kurz A. Deterioration of spontaneous speech in AD patients during a one-year follow-up: Homogeneity of profiles and factors associated with progression. Dementia 1996;7:35-40.
35. Chapman SB, Zientz; J, Weiner M, Rosenberg R, Frawley W, Burns MH. Discourse changing in early Alzheimer disease, mild cognitive impairment, and normal aging. Alzheimer Dis Assoc Disord 2002;16:177-186.
36. Cummings JL, Darkins A, Mendez M, Hill MA, Benson DF. Alzheimer's disease and Parkinson's disease: Comparison of speech and language alterations. Neurology 1988;38:680-684.
37. Sevush S, Leve N, Brickman A. Age at disease onset and pattern of cognitive impairment in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1993;5:66-72.
38. Arkin S, Mahendra N. Discourse analysis of Alzheimer's patients before and after intervention: methodology and outcomes. Aphasiology 2001;15:533-569.
39. Asp E, Song X, Rockwood K. Self-referential tags in the discourse of people with Alzheimer's disease. Brain Lang 2006;97:41-52.
40. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method of grading the cognitive state of patients for the clinician. J. Psychiatry Res 1976;12:189-98.
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth Edition. Washington DC: APA, 1994.
42. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44 (abstract).
43. Reisberg B, Ferris SH, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
44. Bastiaanse R, De Jong J. Klinische linguistiek en grammaticale codering. Stem-Spraak- en Taalpathologie 1996;5:134-151.
45. Cummings JL, Benson DF. Dementia of the Alzheimer type. An inventory of diagnostic clinical features. J Am Geriatr Soc 1986;34:12-19.
46. Almor A, Kempler D, McDonald MC, Andersen ES, Tyler LK. Why do Alzheimer Patients have difficulty with pronouns? Working memory, semantics, and reference in comprehension and production in Alzheimer's disease. Brain and Language 1999;67:202-227.
47. Hier DB, Hagenlocker K, Shindler AG. Language disintegration in dementia: Effects of etiology and severity. Brain Lang 1985;25:117-133.
48. Zec RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R. Alzheimer Disease Assessment Scale: Useful for Both Detection and Staging of dementia of the Alzheimer Type. Alzheimer Dis Assoc Disord 1992;6:89-102.
49. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea and Febiger 1983.
50. Gomez RG, White DA. Using verbal fluency to detect very mild dementia of the Alzheimer type 2006. Arch Clin Neuropsychol 200621:771-775.
51. Tompkins CA. Right hemisphere communication disorders: theory and management. San Diego: Singular Publishing Group, 1995.